companyName

feedTypes

includeDividend

includeEstimates

includeOverview

includeOwnership

includeResearchContent

researchId

CompanyName_Query

companySlug

CompanyMetaData

Company_query

company

query CompanyName_Query(
  $companyName: String!
  $researchId: ID
  $includeResearchContent: Boolean!
  $feedTypes: [ContentType!]!
  $includeEstimates: Boolean!
  $includeOverview: Boolean!
  $includeOwnership: Boolean!
  $includeDividend: Boolean!
) {
  ...CompanyMetaData_Ux1x9
  ...Company_query_3adRh7
}

fragment AnalystData on Analyst {
  name
  pageUrl
  jobTitle
  imgUrl
}

fragment AuthorList on Content {
  __isContent: __typename
  id
  authors {
    __typename
    id
    name
    pageUrl
  }
}

fragment ChangePercentBlock_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      diff1mPercentage
      diff1yPercentage
      diff3yPercentage
      diffFromStartPercentage
    }
    id
  }
}

fragment CompactFeed_3NXCcw on Query {
  compactFeed: feedContent(companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...TeaserExtraCompact_content
        createdAt
        companies {
          viewerIsFollowing
          id
        }
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment CompanyAnalystQuery on Company {
  analysts {
    ...AnalystData
    name
    pageUrl
    jobTitle
    imgUrl
    id
  }
}

fragment CompanyCoverage_Company on Company {
  analysts {
    name
    id
  }
  isPayingCustomerOf
  isFormerCustomerOf
  isCorporateCustomer
  ...CompanyAnalystQuery
  defaultInstrument {
    ...TargetAndRecommendation_Company
    id
  }
}

fragment CompanyDescription_Company on Company {
  description
  websiteUrl
  name
}

fragment CompanyDisclaimer_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    isPayingCustomerOf
    isFormerCustomerOf
    id
  }
}

fragment CompanyDividendER_query on Company {
  name
  defaultInstrument {
    estimateData {
      reportingCurrency
    }
    dividendTransactions: estimateTransactions(first: 1, includeQuarters: false) {
      actualized {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
      estimates {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
    }
    id
  }
}

fragment CompanyDividendNonER_query on Company {
  name
  defaultInstrument {
    nonERDividendSet: nonERCompanyNumberSet(includeQuarters: false) {
      year
      dividend
      dividendYield
      epsReported
      sharePrice
      currency
    }
    id
  }
}

fragment CompanyDividend_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...CompanyDividendER_query
    ...CompanyDividendNonER_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyFinancials_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...NonERCompanyNumbers_query
    ...CompanyNumbers_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyHeader_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    id
    companyInsref
    name
    viewerIsFollowing
    followersCount
    isCorporateCustomer
    hasPinpointData
    hasDividendHistory
    sector {
      sectorname
      industry
    }
    regions
    extensiveResearchExists
    researchContentExists
    defaultInstrument {
      symbol
      priceData {
        tradeCurrency
        lastPrice
        diff1dPercentage
      }
      marketplace {
        name
      }
      estimates: estimateTransactions(first: 1, includeQuarters: false) {
        date
      }
      nonERCompanyNumberSet(first: 1, includeQuarters: false) {
        year
      }
      id
    }
    topOwners {
      holders {
        name
      }
    }
    transactions: insiderTransactions(filter: {types: [BUY, SELL, SUBSCRIPTION]}) {
      edges {
        node {
          date
          id
        }
      }
    }
  }
}

fragment CompanyInsiderTransactions on Company {
  name
  regions
  insiderTransactions(filter: {types: [BUY, EXERCISE_OF_SHARE_OPTION, PLEDGE, RECEPTION_OF_SHARE_PREMIUM, SELL, SUBSCRIPTION]}) {
    edges {
      node {
        insider
        position
        volume
        price
        date
        unit
        type
        relatedParty
        id
      }
    }
  }
}

fragment CompanyInvestorConsensus_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    companyInsref
    id
  }
}

fragment CompanyMetaData_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    description
    pageUrl
    websiteUrl
    logoUrl
    squareLogoUrl
    defaultInstrument {
      isin
      symbol
      marketplace {
        name
      }
      estimateData {
        modelType
      }
      id
    }
    id
  }
}

fragment CompanyName_Slug on Company {
  slug
}

fragment CompanyNumbers_query on Company {
  name
  defaultInstrument {
    estimateData {
      modelType
      reportingCurrency
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      comparisonIndexName
      actualized {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
    }
    id
  }
}

fragment CompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      companyTransactions: estimateTransactions(first: 1, includeQuarters: false) {
        actualized {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
        estimates {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
      }
      id
    }
    id
  }
}

fragment CompanyOwners on Company {
  regions
  topOwners {
    recordDate
    compareDate
    source
    holders {
      name
      capitalPercent
      votingPowerPercent
      totalShares
      positionChange
      totalSharesChange
      shareChange
      isNew
      isRemoved
    }
  }
}

fragment CompanyOwnership_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    ...CompanyOwners
    ...CompanyInsiderTransactions
    id
  }
}

fragment CompanyPageBottom_query_2bVJwf on Query {
  ...GeneralFeed_data_3NXCcw
  ...CompactFeed_3NXCcw
  ...UpcomingEventsQuery_Ux1x9
  ...RiskRecommendMatrix_query_Ux1x9
  ...CompanyOverviewGraphs_query_Ux1x9
  ...NonERCompanyOverviewGraphs_query_Ux1x9
  company(companySlug: $companyName) {
    companyInsref
    ...ForumUpdates_Company
    defaultInstrument {
      coreId
      id
    }
    id
  }
  allFeed: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  main: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [COMPANY_REPORT, EQUITY_BRIEF, EXTENSIVE_COMPANY_REPORT, ANALYST_COMMENT, VIDEO, ARTICLE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  webcasts: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [WEBCAST]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  thirdPartyResearch: feedContent(first: 1, companySlug: $companyName, filter: {types: [THIRD_PARTY_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  releases: feedContent(first: 1, companySlug: $companyName, filter: {types: [STOCK_EXCHANGE_RELEASE, PRESS_RELEASE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyPageTop_query_Ux1x9 on Query {
  ...StockChart_ChartQuery_Ux1x9
  ...LatestReports_query_Ux1x9
  company(companySlug: $companyName) {
    isFund
    name
    ...CompanyCoverage_Company
    ...CompanyName_Slug
    ...CompanyDescription_Company
    ...FundNumbers_Company
    ...ChangePercentBlock_Company
    ...KeyEstimateFigures_Company
    ...InvestmentCompanyKeyFigures_Company
    defaultInstrument {
      id
      estimateData {
        modelType
      }
    }
    analysts {
      name
      id
    }
    id
  }
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EQUITY_BRIEF, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EQUITY_BRIEF, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment Company_query_3adRh7 on Query {
  ...CompanyHeader_query_Ux1x9
  ...CompanyOwnership_query_Ux1x9 @include(if: $includeOwnership)
  ...CompanyFinancials_query_Ux1x9 @include(if: $includeEstimates)
  ...CompanyDividend_query_Ux1x9 @include(if: $includeDividend)
  ...CompanyInvestorConsensus_query_Ux1x9
  ...CompanyPageTop_query_Ux1x9 @include(if: $includeOverview)
  ...CompanyPageBottom_query_2bVJwf @include(if: $includeOverview)
  ...CompanyDisclaimer_query_Ux1x9
  ...Extensive_query_36E2lH
  ...ResearchContent_query_14bL89
}

fragment Extensive_query_36E2lH on Query {
  company(companySlug: $companyName) {
    extensiveResearch(researchId: $researchId) {
      publishedAt
      pageUrl
      pdfUrl
      content {
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
        isOutdated
      }
    }
    id
  }
}

fragment ForumUpdates_Company on Company {
  name
  forum {
    threadUrl
    highlightedPosts {
      url
      author
      authorImgUrl
      text
      postedAt
      likesCount
    }
  }
}

fragment FundNumbers_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      lastPrice
      ath
    }
    id
  }
}

fragment GeneralFeed_data_3NXCcw on Query {
  generalFeed: feedContent(first: 20, companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        companies {
          name
          id
        }
        ...Teaser_content
        ...TeaserCompact_content
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment InvestmentCompanyKeyFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
    }
    estimateData {
      modelType
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      actualized {
        year
        quarter
        sharesTotal
        marketCap
        nav
        navPerShare
        dividendYield
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        dividendYield
      }
    }
    id
  }
}

fragment KeyEstimateFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
      lastPrice
      marketCap
    }
    sector
    fundamentalData {
      ebit
      eps
      sales
      dividend
    }
    estimateData {
      modelType
      estimates {
        firstEstimateYear {
          year
          bookValue
          netSales
          dividendA
          epsAdjusted
          ebitAdjusted
          hybridLoan
          noOfShares
          netDebt
          mvMinorities
          mvAssociated
          roePercent
        }
      }
    }
    estimatesSharePrice: estimateTransactions(first: 1) {
      estimates {
        sharePrice
      }
    }
    id
  }
}

fragment LatestReports_query_Ux1x9 on Query {
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EQUITY_BRIEF, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EQUITY_BRIEF, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
}

fragment NonERCompanyNumbers_query on Company {
  name
  defaultInstrument {
    nonERNumberSet: nonERCompanyNumberSet(includeQuarters: true) {
      year
      quarter
      revenue
      ebitda
      ebitReported
      epsReported
      dividend
      sharesTotal
      roe
      roi
      enterpriseValue
      marketCap
      gearingRatio
      equityRatio
      dividendYield
      sharePrice
      currency
      evSales
      evEbitda
      evEbit
      pb
      netIncome
      ptp
    }
    id
  }
}

fragment NonERCompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      overviewGraphsData: nonERCompanyNumberSet(includeQuarters: false) {
        year
        revenue
        ebitReported
        epsReported
        dividend
        dividendYield
        currency
      }
      id
    }
    id
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ResearchContent_query_14bL89 on Query {
  company(companySlug: $companyName) {
    slug
    researchContentFeed @include(if: $includeResearchContent) {
      __typename
      id
      ...Teaser_content
    }
    researchContentIds @include(if: $includeResearchContent)
    researchContent(researchId: $researchId) @include(if: $includeResearchContent) {
      publishedAt
      pdfUrl
      content {
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
      }
    }
    id
  }
}

fragment RiskRecommendMatrix_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      riskData: estimateTransactions(first: 1) {
        businessRisk
        valuationRisk
      }
      id
    }
    id
  }
}

fragment StockChart_ChartQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    isFund
    defaultInstrument {
      coreId
      id
      marketOpen
      marketClose
      marketplace {
        region
      }
      priceData {
        lastPrice
      }
      returns {
        day
        week
        month
        threeMonths
        sixMonths
        year
        threeYears
        fiveYears
        tenYears
        ytd
        total
      }
    }
    id
  }
}

fragment TargetAndRecommendation_Company on Instrument {
  estimateData {
    modelType
    researchCurrency
    estimates {
      date
      recommendation
      targetPrice
    }
  }
}

fragment TeaserCompact_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  isPremium
  pageUrl
  lang
  companies {
    ...CompanyTagList
    id
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  ...AuthorList
}

fragment TeaserExtraCompact_content on Content {
  __isContent: __typename
  id
  title
  createdAt
  pageUrl
  lang
  companies {
    name
    pageUrl
    viewerIsFollowing
    id
  }
}

fragment Teaser_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  pageUrl
  imgUrl
  isPremium
  lang
  companies {
    ...CompanyTagList
    id
  }
  publishers {
    imgUrl
  }
  authors {
    __typename
    id
  }
  ... on AnalystComment {
    preview
  }
  ... on Article {
    preview
  }
  ... on CompanyReport {
    preview
  }
  ... on ThirdPartyCompanyReport {
    preview
  }
  ... on QA {
    preview
  }
  ... on Video {
    preview
    liveTime
    videoDuration
  }
  ... on Webcast {
    preview
    liveTime
  }
  ...AuthorList
  ...Reactions
}

fragment UpcomingEventsQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      calendarEvents(first: 10) {
        edges {
          node {
            date
            type
            period
            id
          }
        }
      }
      id
    }
    id
  }
}


name

description

pageUrl

websiteUrl

logoUrl

squareLogoUrl

defaultInstrument

companyInsref

viewerIsFollowing

followersCount

isCorporateCustomer

hasPinpointData

hasDividendHistory

sector

regions

extensiveResearchExists

researchContentExists

topOwners

insiderTransactions

isPayingCustomerOf

isFormerCustomerOf

extensiveResearch

slug

feedContent

Hansa Biopharma

Hansa Biopharma AB: Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

Hansa Biopharma AB: Hansa Biopharma participating at LSX Nordic Congress

Hansa Biopharma AB: Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Redeye: Hansa Biopharma (Q1 update): Soft Quarter Creates Opportunity

Hansa Biopharma AB: Hansa Biopharma Report First Quarter 2026 Financial Results

Hansa Biopharma AB: Hansa Biopharma to host Q1 2026 interim results conference call

Hansa Biopharma AB: Hansa Biopharma publishes 2025 Annual and Sustainability Reports

Hansa Biopharma AB: Hansa Biopharma announces a USD 30 million convertible note financing

Hansa Biopharma AB: Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science

Hansa Biopharma AB: Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026

Hansa Biopharma AB: Hansa Biopharma participating at LSX Investival Showcase USA

Hansa Biopharma AB: Hansa Biopharma participating at Leerink Global Healthcare Conference

Hansa Biopharma AB: PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026

Hansa Biopharma AB: Hansa Biopharma presenting at TD Cowen's 46th Annual Health Care Conference

Hansa Biopharma AB: Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Redeye: Hansa Biopharma (Q4 update): Strong Quarter in Europe

Hansa Biopharma AB: Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Hansa Biopharma AB: Hansa Biopharma to host Year-end report 2025 conference call

Hansa Biopharma AB: Hansa Biopharma has won the 2025 SwedenBIO Award

Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

Hansa Biopharma AB: Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference

Hansa Biopharma AB: Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease

Hansa Biopharma AB: Hansa Biopharma announce changes to strengthen European and International organisation

Hansa Biopharma AB: Hansa Biopharma presenting at Jefferies Global Healthcare Conference and DNB Carnegie's 16th Annual Nordic Healthcare Conference

NASDAQ Stockholm

Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients.

Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

One can’t help but analyze this. Of individual companies, I have spent by far the most working hours on this, even though the result is meager. For instance, with the timing of Faron, Hims, and Optomed, I’ve succeeded significantly better than with holding this, but what can you do…  In any case, I ventured to make a small estimate of Hansa’s development over the next couple of years.  I assume here that in Europe, talk of an S-curve can be forgotten, and imlifidaasi sales will develop more linearly when viewed on an annual basis. At the quarterly level, there is so much fluctuation that an analysis is not meaningful. I also believe that peak sales in Europe for kidney transplants will remain significantly lower than analysts have predicted. In my opinion, Hansa’s development looks like a struggle for survival until 2027, but after that, the company still has a chance to meet expectations. I would see that, quite credibly, with US sales, there are opportunities for much better and faster success than in Europe, but that is a matter for a different review from 2027 onwards. Assumptions: Anti-GBM			Launch 2027  Kidney transplantation USA	Launch 2027  DMD			Launch 2027  GBS			Launch 2028 Product sales and revenue are assumed to grow trend-wise in 2025-2026 based on the development in 2021-2024. Additionally, the growth in revenue and product sales is assumed to transfer as such to profit and cash flow in 2025-2026, meaning costs remain unchanged. It’s difficult to see significant leaps in the next couple of years, but Sarepta’s milestone payments might bring “unforeseen” good, which may not be fully reflected here. On the other hand, total costs remaining unchanged is also quite an optimistic simplification, even if R&D costs might temporarily decrease slightly in the coming quarters. Things should then start happening in 2027-2030, but it’s a long way off. Of those 2027 launches, a few might, in the best case, be in 2026, but actual sales will likely only come in 2027 at best. Things can always shift further into the future. The cash position is indeed SEK 400m. Hansa still states that funding is sufficient until 2026. That doesn’t align with my analysis at all, meaning one of us is wrong. Hopefully me  Disclaimer: the analysis is entirely my own; errors may exist. Edit: I was still thinking about Hansa’s forecast for cash sufficiency until 2026 and the S-curve – which has now been removed from Hansa’s presentations. Here is a bullish version of the curves. Assumptions are otherwise the same, but here, the development between 2023-2024 has been emphasized, and an assumption has been made that sales development will continue to accelerate based on this, following an S-curve. I personally believe more in the first version, but it will be interesting to see which one 2025 follows.

Q2 2025. No major surprises, unless one counts the fact that the illustrative “Quarter on Quarter Performance” chart, which was included in the previous report, has been dropped from the report – perhaps it wouldn’t give a sufficiently positive picture of the development. So I compiled one myself, the result is below. Revenue 49.1 MSEK, almost entirely product sales (approx. 16 commercially treated Idefirix patients). Sarepta’s problems are likely reflected in the fact that there are hardly any contract revenues. During the period, a directed share issue of 232 MSEK was carried out, about half of which was consumed as cash flow during the quarter. At the same time, the NovaQuest loan restructuring was agreed upon. The development of cash flow (= costs) is, in itself, a positive aspect of the report.

Hansa’s Q1 2025 report is out. An hour before its release, CEO Søren Tulstrup was fired, effective immediately. Renée Aguiar-Lucander (Linkedin) starts as the new CEO and will already participate in today’s conference call.  Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB where she successfully led the company through a dual listing on NASDAQ in both Sweden and the U.S. During her tenure, the company successfully launched and commercialized the first ever approved drug for immunoglobulin A (IgA) nephropathy - -. Prior to that, Aguiar-Lucander had a long and successful career in the healthcare investment sector -  The Q1 result was not as terrible as one might have feared from the news of the CEO change, but it was by no means good. Revenue was 66.3 MSEK, which was almost entirely Idefirix sales. Commercially treated patients numbered approximately 22, which is certainly an increase from the previous quarter’s downturn, but otherwise quite flat compared to last year. Cash flow was negative by 151.9 MSEK, and cash reserves are now less than two quarters’ worth, i.e., 250 MSEK. The new CEO’s fundraising skills will be needed.              hansabiopharma.com              20250423-hnsa--q1-2025-quarterly-report-eng.pdf    1599.76 KB                                              hansabiopharma.com              Hansa Biopharma appoints new Chief Executive Officer | Hansa Biopharma

Anti-GBM (GOOD-IDES-02) pivotal phase 3 failed, Hansa announced this morning. Quite a big and surprising disappointment for me. This emphasizes that one cannot draw very big conclusions from comparisons to historical cohorts yet in phase 2, no matter how good it looks. The phase 3 primary endpoint (eGFR 6 months) did not differ in the imlifidase+SoC arm from control-SoC. Although imlifidase rapidly removed anti-GBM antibodies and approximately 60% of patients were dialysis-free at 6 months, the control group achieved almost the same level, resulting in no statistical difference. In phase 2, there was talk of a historical control group that achieved only about 20-25% dialysis-free status. A key reason why phase 3 “lost” to phase 2 is the study design: phase 2 was open-label, uncontrolled, and compared results to that (perhaps too loosely) selected historical cohort, whereas in phase 3, the standard of care was defined in the protocol as exceptionally aggressive (immediate and intensive PLEX + cyclophosphamide + steroids). This significantly raised the results of the control group and eroded the incremental benefit of imlifidase, even though the biological effect itself worked as expected. In other words, imlifidase did work, but when the disease was diagnosed quickly and aggressive SoC was started immediately in this experimental setup, there was no additional benefit from imlifidase. In practice, the regulatory pathway for the anti-GBM indication is non-existent after this, and the value of this indication can be set to zero in Excel.                   hansabiopharma.com              Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement...                                                clinicaltrials.gov              ClinicalTrials.gov

A rather weak Q3 from Hansa. One can probably already conclude that there simply isn’t a proper market for Idefirix in Europe for the kidney transplant indication. Revenue 30.8 MSEK, significantly less than a year ago. This corresponds to about ten treated patients. Sales in Germany are in trouble after Germany suspended its participation in the Eurotransplant prioritization program, and there are also problems in Spain. This also indicates weak future quarters. The “launch,” if the sales effort can still be called that, is thus going in the wrong direction in Europe. The cash situation is, of course, good after a directed issue made at a surprisingly good price. The issue raised 671.5 MSEK (71.5 MUSD) at the beginning of October, with a subscription price of almost SEK 40. The dilution with these issues is quite significant.  Quote from the Q3 report:  As mentioned in the Q2 report, the German Eurotransplant Prioritized Program has been paused, and as a result no product sales were reported in Germany during Q3. While physicians in Germany can continue prescribing IDEFIRIX under the standard Eurotransplant Kidney Allocation System (ETKAS), we expect that the pause of the prioritized program will continue to have a negative impact in the near- to mid-term.  This situation in Germany was explained in the Q2 Q&A session mainly by concerns in Germany about patient equality:  When it comes to these highly sensitized patients, you – they end up in this priority program for specific reasons. Let’s say, they’ve had a previous transplant, they have been pregnant, they’ve had a blood transfusions. You know the reason why they’re highly sensitized. And in Germany, what they have really been discussing is this health equity. That certain patients end up in this program.  Here, it seems to be implied that at least some patients are sensitized “due to their own reasons,” meaning they might not have properly managed their immunosuppressive medication with the first transplant or otherwise cause problems with their lifestyle. At least such a comment came from a German doctor earlier. Since kidneys are a very limited resource, they are preferably given to a non-sensitized recipient without the cost of Idefirix. This perspective is quite bad for Hansa. And there are also problems with Idefirix reimbursement in Spain. The story relies increasingly on the USA and, of course, on future indications in the development pipeline. Unfortunately, the FDA is also currently closed, which is unlikely to speed up the project… Fortunately, I realized at some point to start trading this – buying below SEK 30 and selling above SEK 35 has been a significantly better strategy than ‘hodling’ in recent years. At some point, this might still take off if the USA succeeds, and before that, it would be good to be involved if one believes in the story. After the Q3 report, we are at least back at buying prices. Of course, there is a lot of optimism in the report about the future and indications in the development pipeline, but in the short term, it left a rather melancholic feeling nonetheless.            hansabiopharma.com              hnsa--q3-2025-eng-final-1.pdf    2.07 MB

Hansa opened with a modest -25% decline after the auction following the Q4 report. Now it’s “only” -17%. The explanation is mainly only nine commercially treated patients and still a severely poor cash flow. Revenue 32.3 MSEK, cash flow -206.8 MSEK, cash 405.3 MSEK. Why wasn’t money raised after the good news in December or earlier last year? Now it has to be raised with a potentially quite modest valuation.              hansabiopharma.com              20250206-hansa-biopharma-q4-and-fy-2024-report.pdf    1431.99 KB                                              redeye.se              Hansa Biopharma: Ends 2024 on a softer note    After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m.   Hansa does not expect to record any material provisi

Let’s post a summary of Q4 2025 here, even if it’s a bit late. For a change, it was actually a pretty good quarter. Revenue was 76 MSEK, of which product sales accounted for 61 MSEK, representing about twenty treated Idefirix patients. Full-year 2025 revenue grew by approximately 30% year-on-year. Q4 cash flow was still 178 MSEK in the red, and the full-year cash flow was -549 MSEK accordingly. Cash on hand was 701 MSEK.  Hansa gave guidance for a weaker Q1 2026 than the quarter just ended, and improvement could come in the latter half of the year. The US launch is planned for the end of the year (Q4), and hope for this was partly bolstered by Hansa reporting that the FDA accepted the BLA (Biologics License Application) for imlifidase on Feb 18. Personally, I only skimmed through this report, although I still have some kind of Hansa position in my portfolio. However, I spotted something in Redeye’s Q&A section, according to which Redeye does not see the shortage of donated kidneys in the US market as a similar constraint as in Europe. According to analyst Richard Ramanius, the target group for imlifidase is prioritized in the US: “Hansa has an advantage in that US decision makers prioritise highly sensitised patients because they want to reduce dialysis dependence.” Redeye has certainly been quite off the mark with its Hansa analysis so far, so it’s hard to say what value this statement holds. At least the analyst has changed now. Expectations still rest mainly on that US launch and the US market potential.            hansabiopharma.com              hnsa--q4-2025-eng-final.pdf    2038.10 KB

Redmile Group

Polar Capital LLP

Hansa Biopharma

33.22 SEK

-0.72 %